Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (27277)	1/6/1999 9:57:00 PM
From: tonyt	Read Replies (2) \| Respond to of 32384

>Everyone here knows the deal: If these 2 drugs get approved >we're O.K. if not we'll open at around $4 the next morning regardless >of any earnings report. Why would you think it would crash to $4. Ligand has more that 2 drugs in the pipeline.

To: LLCF who wrote (27277)	1/6/1999 10:34:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< Jeezus!!!!!!!!! Enough about the freakin earnings report already!!!!! Who gives a flying one???? NOBODY. >> Sorry Dave, one last comment on the subject and then I promise to drop it. <g> << FUTURE earnings/burn are what count not past losses. >> I agree. I don't think that looking at Ligand's, or any clinical stage biotech company's net income is as meaningful as looking at the quarter's funding, burn rate and pipeline activity. Ligand's recent funding has been $20 million and $30 million issue price from the Elan deal and $12.5 million from the warrant deal. That, to me, is a very significant 4th quarter impact on Ligand's ability to fund it's pipeline. I don't care if Ligand funds it's pipeline thru revenues listed on the income statement, or from revenues listed on the balance sheet. The important thing, as you so stated, is future earnings and burn (plus stock dilution). Some of the CPAs on this thread might have a bird, but when the 4th quarter earnings press release comes out, the first items that I will look at is "cash on hand", revenues and net loss. Then I will peruse the report to see what Robinson has to say. Anyway, David, have a good night, Bob